Biotech Values

[DewDiligence]

You’re flat-out wrong vis-à-vis DNDN’s disseminating dollar-denominated numbers for Provenge. To wit:

http://www.reuters.com/article/idUSN249260820090924

The company said it will steadily ramp up production until full capacity is achieved by late 2011 at plants in New Jersey, Atlanta and Los Angeles, together able to support potential annual sales of $1.2 billion to $2.5 billion.

This is what the Seeking Alpha blogger was referring to. Conservative companies generally don’t say stuff like this before a product has been approved for marketing.